Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > JD, I’d love to see an update!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(42)
•••
Comment by MineDiggeron Jun 18, 2021 2:24am
179 Views
Post# 33409755

RE:RE:JD, I’d love to see an update!

RE:RE:JD, I’d love to see an update!
anyone know what the "obvious ... reasons" were?

"It was obvious at the end of Q1, for various reasons, that Bioasis would be quiet for a while."

And anyone know of anything else "obvious" which they might like to share with us with less insight?

For instance, what is not obvious to me is why the current CP is still dated March, and thus still has those missed "Q1, CY2021" dates on the Pipeline slide. Not to mention not taking advantage of the recent aducanumab publicity to highlight relevent Bioasis skills (as per prophetoffacts post and post).

I mean what is the point of the "emerged with Sachs Associates, Equity Guru and Proactive Investor" if you can't even produce an up-to-date pdf?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities